Celgene agrees to buy biotechnology company Juno Therapeutics for about $9 billion. » Read More
There were no signs of forced entry on the cold December morning when a Canadian billionaire businessman and his wife were found dead inside their mansion. » Read More
By: Meg Tirrell
The French drugmaker is nearing a deal to acquire biotechnology company Bioverativ for $105 a share. » Read More
Trump's pledges to repeal and replace Obamacare may have caused a surge in women getting IUDs.
As a government shutdown becomes reality, national health agencies such as the FDA, CDC and NIH face major setbacks.
Amazon held a secret meeting a year ago with creative thinkers focused on innovative models for delivering care.
With a nasty flu season underway, businesses can expect to see billions of dollars in lost productivity, according to Andy Challenger.
The flu is widespread across the U.S., but it's not too late to get a flu shot.
Thirty children have died from the flu so far, and hospitalizations are higher than they normally have been for this time of year.
Flu is especially bad this season, and going into work while we're sick risks spreading flu further.
Funding for a program that covers 9 million kids expired. Republicans want something in return for extending it, Vox reports.
The Trump administration takes two new steps in its ongoing fight against abortion.
Every decade our wellness and longevity lengthens by two years. That is about to get even better.
President Donald Trump has repeatedly condemned high drug prices but hasn't done much to lower them one year in office.
Cozying up to health investors is now a full-time job.
Jim Cramer said an overload of buyers in the stock market is resulting in dramatically rising stock prices.
A consortium representing more than 450 hospitals plan to create their own generic drug company.
Ethan Perlstein didn't shy away from sharing everything with CNBC, including his personal salary, rejections and revenues.
Buying Juno could help Celgene diversify its portfolio as its top-selling drug approaches patent expiration.
Get the best of CNBC in your inbox